Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
United Therapeutics clinical trials
Also known as UTHR.
The registry lists 103 studies whose lead sponsor is United Therapeutics or one of 4 companies grouped under it. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the United Therapeutics studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to United Therapeutics.
- United Therapeutics83 studiesSame company
Something wrong?
- Lung Biotechnology PBC8 studies →Subsidiary
Something wrong?
- Miromatrix Medical Inc.6 studies →Acquired — became part of United Therapeutics, Dec 12, 2023 · source ↗
Something wrong?
- Unither Pharmaceuticals4 studies →Subsidiary
Something wrong?
- Lung Bioengineering Inc.2 studies →Subsidiary
Something wrong?
Focus areas
Conditions United Therapeutics leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 103. Browse all 103 →
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung DiseaseEnrolling by invitationNCT04905693Phase 3
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionEnrolling by invitationNCT03683186Phase 3
- Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRDRecruitingNCT07224763Phase 1/2
- DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)RecruitingNCT06388421
- Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)RecruitingNCT05943535Phase 3
- Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRDRecruitingNCT06878560Phase 1/2
- Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisCompletedNCT05255991Phase 3
- Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP FacilityCompletedNCT03641677Not applicable
Sponsor listed in the registry: Lung Bioengineering Inc.
- Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH SubjectsTerminatedNCT04084678Phase 3
- A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH PatientsCompletedNCT03626688Phase 3
- Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier DetectionCompletedNCT05776225
- Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)TerminatedNCT03794583Phase 3
- Extending Preservation and Assessment Time of Donor Lungs Using the Toronto EVLP System™ at a Dedicated EVLP FacilityCompletedNCT02234128Not applicable
Sponsor listed in the registry: Lung Bioengineering Inc.
- Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisCompletedNCT04708782Phase 3
- ADAPT - A Patient Registry of the Real-world Use of Orenitram®Active, not recruitingNCT03045029
- miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 TrialCompletedNCT06285253Phase 1
Sponsor listed in the registry: Miromatrix Medical Inc. · First submitted after Miromatrix Medical Inc. became part of United Therapeutics
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial HypertensionActive, not recruitingNCT05203510Phase 4
- Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 YearsCompletedNCT02276872Phase 2
- Evaluate Real-World Use of Next Generation Infusion Pumps to Administer RemodulinTerminatedNCT05060315
- Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using TyvasoCompletedNCT03950739Phase 1
- Open-Label Study of Oral Treprostinil in Digital UlcersTerminatedNCT00848107Phase 2
- Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the NewbornTerminatedNCT02261883Phase 2
- TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)CompletedNCT03055221Phase 4
- A Pharmacokinetic Substudy of the TDE-PH-304 ProtocolCompletedNCT01934582Phase 3
- Rapid Switch From Flolan to Remodulin in the Outpatient ClinicTerminatedNCT00643604Phase 4
- Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAHTerminatedNCT00439946Phase 4
- FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)CompletedNCT00325403Phase 3
- Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)CompletedNCT00147199Phase 3
- Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil DiethanolamineCompletedNCT00775463Phase 2
- Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®CompletedNCT01477333Phase 2
- Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant RecipientsWithdrawnNCT01884038Phase 2/3
- A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT03496623Phase 3
- EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial HypertensionCompletedNCT03497689Phase 4
- An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFETerminatedNCT02633293Phase 2/3
- Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFECompletedNCT02630316Phase 2/3
- An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionCompletedNCT01560637Phase 3
- Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial HypertensionCompletedNCT02279745Phase 2
- A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPDTerminatedNCT03857841Phase 1
- An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial HypertensionCompletedNCT01027949Phase 3
- Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAHCompletedNCT03888365
- Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung CancerCompletedNCT03098030Phase 2/3
- Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection FractionTerminatedNCT03037580Phase 3
- Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEFTerminatedNCT03043651Phase 3
- Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)CompletedNCT00989963Phase 2
Sponsor listed in the registry: Lung Biotechnology PBC
- A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial HypertensionTerminatedNCT03657095Phase 3
Sponsor listed in the registry: Lung Biotechnology PBC
- Beraprost-314d Added-on to Tyvaso® (BEAT)CompletedNCT01908699Phase 3
Sponsor listed in the registry: Lung Biotechnology PBC
- Safety and Efficacy of APD811 in Pulmonary Arterial HypertensionCompletedNCT02279160Phase 2
- A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH PatientsCompletedNCT00781885Phase 2
Sponsor listed in the registry: Lung Biotechnology PBC
- Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral MonotherapyCompletedNCT01560624Phase 3
- An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) PatientsCompletedNCT00792571Phase 2
Sponsor listed in the registry: Lung Biotechnology PBC